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ABSTRACT 
Introduction: The a.2 agonis~ · dexmedetomidine is a n~~ sedative and analgesic 
agent which is licensed in the USA for post-operative intensive care sedation. We 
compared dexmedetomidine with the mixture of midazolam and morphine for 
post-operative patient who required mechanical ventilation in intensive care unit 
(ICU). 
Objedive: To compare the effect of dexmedetomidine and midazolam-morphine 
mixture among post-operative patients in ICU; in term of the amount of analgesic 
(PCA morphine) requirement, s~dation score, haemodynamic profiles and time 
of extubation. 
Methodology: Prospective, double-blinded randomized controlled trial study 
design involved post-operative patients admitted to the Intensive Care Unit {ICU) 
of Hospital Universiti Sains Malaysia (HUSM) conducted from June 2003 to June 
2004. Thirty-four mechanically ventilated post-operative patients were randomly 
assigned to receive short-term (minimum 4 hours) sedation with either 
continuous intravenous infusion of dexrnedetomidine (group Dex, n=17) or 
midazolam-morphine mixture (group MM, n=17). Both groups received similar 
intraoperative anaesthetic regime. Patient controlled analgesia (PCA Morphine) 
was given to patient as rescue analgesic. Analgesic (PCA morphine) used 
(mg/hour), Ramsay sedation scoring, extubation time (minute), systolic blood 
pressure, diastolic blood pressure, mean arterial pressure and heart rate were 
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Medical Sciences, Universiti s.ains Malaysia had approved this study on 9th April 
2003. 
Result: Mean extubation time of dexmedetomidine group was significantly lower 
than midazolam and morphine mixture group [mean {s.d.): 40.3 ± 16.5 minutes 
versus 57.9 ± 17.7 minutes, p=O.OS]. Within the first 4 hours drug infusion, mean 
systolic blood pressure [mean (s.d.): 105 ± ·14 mmHg vs 127 ± 24 mmHg, 
(p=O.OOO)], mean diastolic blood pressure [mean {s.d.): 59± 8mmHg vs 66 ± 13 
mmHg (p=O.OOO)], mean arterial pressure [mean {s.d.): 76 ± 9 mmHg vs 86 ± 15 
mmHg (p=O.OOO)] and mean heart rate [mean (s.d.): 88 ± 13 beats per minute vs 
102 ± 24 beats per minute (p=O.OOO)] were significantly lower in 
dexmedetomidine group than tho!?e in midazolam and morphine mixture. There 
was significant difference of mean Ramsay sedation score between 
dexmedetomidine and midazolam morphine mixture {p=O.OOO). However, there 
was no significant difference of mean dose of morphine per hour between 
dexmedetomidine groups and midazolam morphine mixture [(mean (s.d.); 1.4 ± 
0.7 mglhour) versus mean (s.d.}; 1.1 ± 0.8 mg/hour), p= 0.157 ]. 
Conclusion: Dexmedetomidine provides safe, effective sedation and analgesia 
for postoperative long surgical patient in intensive care unit. Haemodynamic 
variables of dexmedetomidine group was more stable than midazolam and 
morphine mixtures group. Thus dexmedetomidine provides better perioperative 
X 
haemodynamic control for a _long surgery. The use of d~xmedetomidine also 
allowed for more rapid trach~al extubation. 
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ABSTRAK 
Pengenalan: a2 agonist dexmedetomidine ialah agen sedatif dan analgesik baru 
yang telah dilesenkan di Amerika untuk sedatif rawatan rapi bagi pesakit selepas 
pembedahan. Kami membandingkan dexmedetomidine dengan campuran 
midazolam dan morfin untuk pesakit selepas pembedahan yang memerlukan 
ventilasi mekanikal di unit rawatan rapi (ICU). 
Objektif: Untuk membandingkan di antara dexmedetomidine dan campuran 
midazolam dan morfin di kalangan pesakit selepas pembedahan di Unit Rawatan 
Rapi (ICU); dalam segi jumlah keperluan analgesia (PCA morphine), skor sedatif, 
profil hemodinamik dan masa ekstubasi. 
Methodologi: Kajian prospektif secara 'double-blinded randomized controlled trial' 
melibatkan pesakit selepas pembedahan yang dimasukkan ke Unit Rawatan 
Rapi (ICU), Hospital Universiti Sains Malaysia (HUSM) di antara Jun 2003 
hingga Jun 2004. 34 pesakit selepas pembedahan dengan ventilasi mekanikal 
telah diagihkan secara rawak untuk menerima sedatif jangka pendek iaitu 
samada infusi intravena berterusan dexmedetomidine (kumpulan Dex, n = 17) 
atau campuran midazolam morphine (kumpulan MM, n = 17). Kedua .. dua 
kumpulan menerima regim anesthetic intra-operatif yang sama. PCA Morphine 
telah diberikan kepada pesakit sebagai analgesik tambahan, jika diperlukan. 
Penggunaan analgesik (PCA morphine) (mg/hour), pemarkahan sedatif Ramsay, 
masa ekstubasi (minit), tekanan darah sistolik, tekanan darah diastolik, purata 
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tekanan arteri dan kadar jant~ng telah diukur. Jawatankuasa Penyelidikan dan 
Etika, Pusat Pengajian Sains Perubatan, Kampus Kesihatan, Universiti Sains 
. · ... 
Malaysia telah meluluskan kajian ini pada 9 April2003. 
Keputusan: Purata masa ekstubasi pesakit dexmedetomidine didapati lebih 
rendah secara signifikan berbanding campuran midazolam morphine [purata 
(s.d.): 40.3 ± 16.5 minit berbanding 57.9 ± 17.7 minit, nilai p kurang 0.05]. 
Dalam masa 4 .jam pertama infusi ubat, purata tekanan darah sistolik [purata 
(s.d.): 105 ± 14 mmHg vs 127 ± 24 mmHg (nilai p kurang 0.000)], purata 
tekanan darah diastolik [purata (s.d.): 59± 8 mmHg vs 66 ± 13 mmHg (nilai p 
kurang 0.000), purata tekanan arteri [purata (s.d.): 76 ± 9 mmHg vs 86 ± 15 
mmHg (p = 0.000)] (nilai p kurang 0.000) dan purata kadar jantung [purata (s.d.): 
.88 ± 13 denyutan seminit vs 102 ± 24 denyutan seminit {nilai p kurang 0.000) 
didapati lebih rendah secara signifikan berbanding campuran midazolam 
morphine. Terdapat perbezaan signifikan peratusan skor sedatif Ramsay di 
antara dexmedetomidine dan midazolam morphine mixture (p = 0.000). Tetapi, 
didapati tiada perbezaan signifikan purata dos morphine per jam di antara 
kumpulan dexmedetomidine dengan campuran midazolam morphine [(purata 
(s.d.); 1.4 ± 0.7 mg/jam) berbanding purata (s.d.); 1.1 ± 0.8 mg/jam), nilai p = 
0.157]. 
Kesimpulan: Dexmedetomidine adalah sedatif yang selamat. efektif dan 
analgesik untuk pesakit pembedahan lama di Unit Rawatan Rapi. Variabel 
Xll1 
hemodinamik bagi kumpulan dexmedetomidine didapati lebih stabil daripada 
kumpulan campuran mic!azolam morphine. Ole~_. itu. dexmedetomidine 
memberikan kawalan hemodinamik peri-operatif lebih baik untuk pembedahan 
yang makan masa lama. Penggunaan dexmedetomidine juga memudahkan 
ekstubasi trakea lebih cepat dilakukan .. 
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CHAPTER 1: INTRODUCTION 
The postsurgical mechanically ventilated patients {e.g. as illustrated in Fig. 1) in 
the intensive care unit (ICU) often experience anxiety, pain and sleep deprivation 
due to the stressful nature of ICU environment (Wheeler, 1993). So, the 
important goals in the treatment of ICU patients are to achieve sedation {while 
maintaining reusability and cooperation), analgesia and anxiolysis with minimal 
haemodynamic and respiratory effects (Bhana, 2000). 
The commonly used agents in the ICU include sedatives (e.g. midazolam, 
lorazepam, diazepam, propofol) and analgesics (e.g. opiates like morphine). 
However, these drugs are associated with complications such as respiratory 
depression, lack of orientation, severe hypotension and gastrointestinal 
hypomotility (Cohen, 2002). The choice of appropriate sedative agents is often 
difficult and must be individualized for each patient. Among characteristics of an 
ideal sedative include easily titratable level of adequate sedation, rapid onset of 
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action, short acting, no adverse effects, no interactions with common ICU drugs, 
ease of administration, lack of accumulation with prolonged administration, easily 
prepared with long shelf-life and cost effective (Cohen, 2002). However, the 
introduction of emerging sedative agents such as dexmedetomidine which 
produce sedative, analgesic and anxiolytic effects with haemodynamic stability 
can broaden clinician options in managing ICU patients (Lawrence, 1996). Since 
2000, dexmedetomidine has been approved in the United States for use as 
sedative for patient in the ICU. It has shown clinical efficacy in providing sedation 
and analgesia in postsurgical ventilated patients (Bhana, 2000). It was also 
approved by the FDA as a short ... term sedative (less than 24 hours) and 
analgesic in the critical care setting especially during the early postoperative 
period (Shapiro, 1995). 
Dexmedetomidine is a lipophilic imidazole derivative and active dextroisomer of 
medetomidine, a widely used veterinary anaesthetic (Savoia and Virtanen, 1991). 
It is a highly selective a- adrenoreceptor agonist with 8 times greater affinity for 
the a2 adrenoreceptor than clonidine (Coughlan et al., 1992). It is also shorter 
acting than clonidine. It stimulates a2 adrenergic receptors in the locus ceruleus 
to provide sedation by reducing sympathetic activity and the level of arousal 
(Lawrence, 1996). In the spinal cord, it enhances analgesia. It also causes 
sympatholysis via central and peripheral mechanisms. The advantages of 
dexmedetomidine as sedative in the ICU include: (i) patient can be extubated 
without prior discontinuation because it does not cause respiratory depression 
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(ii) as dexmedetomidine i~fusion can be continued during the postextubation 
period, the drug allows ~sier weaning process (!i_i) easy arousability of treated 
patients i.e. they can be calmly and easily awakened (Shapiro, 1995). Other 
advantages of dexmedetomidine include reduction in the need for supplemental 
propofol and midazolam of sevenfold and fourfold respectively and 50% 
reduction for morphine requirements. Meanwhile, some adverse effects of 
dexmedetomidine . are hypotension, hypertension (with loading dose) and 
bradycardia (Bhana, 2000). 
Midazolam is short acting, water-soluble benzodiazepine acting on the GABA 
system which provide anxiolysis and amnesia without analgesic properties. It is 
transformed to a lipophilic compound in the blood. It rapidly penetrates the 
central nervous system to produce short onset of sedation of 2-5 minutes. 
Midazolam exhibits dose-related respiratory depression, hypotension, 
vasodilatation (large dose), withdrawal syndrome, tolerance, dependence and 
even addiction (Cohen, 2002). Meanwhile, the opioids (e.g. morphine, fentanyl 
citrate, hydromorphine) are lipid soluble stereospecific agonists at endorphin 
receptor sites in the central nervous ·system and other tissues (Mirski, 1995). At 
low dose, morphine provides analgesia but not anxiolysis. At high doses, they act 
like sedative. Opioids is associated with side effects such as respiratory 
depression, difficult extubation, hypotension, slowing of gastrointestinal motility 
and withdrawal symptoms (Cohen, 2002). 
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CHAPTER 2: LITERATURE REVIEW 
This study compared postoperative monitoring profiles between 
dexmedetomidine and the mixture of midazolam and morphine, in term of 
haemodynamics, sedation score, analgesic requirements and extubation time for 
long operation which required ICU admission. 
2.1 Overview Of Haemodynamic Profiles. Sedation Score. Difference In 
Analgesic's Dosage Reguirements And Time Of Extubation Of Post-Operative 
Patients In ICU Between Dexmedetomidine And Mixtures Of Midazolam 
Morchine Grouos. 
Bloor reported that when dexmedetomidine 1 J..lg/kg administered as a 2-minute 
infusion to six healthy male volunteers caused significant maximum reductions in 
heart rate and blood pressure (17 and 23%, respectively, p<0.005 vs baseline) 
(Bloor et al., 1992). In another two phase Ill trials, patients receiving 
dexmedetomidine 0.2 to 0. 7 JlQ/kg/h consistently had larger mean decreases in 
blood pressure and heart rate during the infusion than placebo recipients 
(Grounds M, 1999). 
In a randomized controlled trial involving 20 adults whom undergone 8 hours 
artificial ventilation, Venn and Grounds had randomized the subjects to receive 
either dexmedetomidine or propofol. If required, an additional analgesia was 
provided by an alfentanil infusion. They found that the patients receiving 
dexmedetomidine significantly lower heart rate, mean (SO) was 72 ( 1 0) beats per 
4 
minute compared to propofol (90 (18)] {p < 0.001) but no differences were found 
in arterial pressures ~tween the groups. The . median (interquartile range) 
Random Sedation Score (RSS) was 5 (4-6) for the dexmedetomidine subjects 
and 5 {4-5) for the propofol group (p =0.68). Then, the percentage of time spent 
at the ideal depth of sedation (i.e. RSS 2-4) was 46.3% (33.1) for the 
dexmedetomidine subjects and 49.1% {43. 7) for the propofol subjects. The 
propofol group received three times more alfentanil compared with patients 
sedated with dexmedetimidine (2.5 (2.2 - 2.9) mg per hour versus 0.8 {0.65 -
1.2) mg per hour {P= 0.004). Mean (range) extubation time in dexmedetomidine 
(Dex) group of subjects was 29 (15-50) minutes which almost similar to propofol 
group i.e. 28 (20-50) minute (Venn and Ground, 2001). 
In the European multicentre trial, about 119 post-operative cardiac and general 
surgical patients who required ventilation and sedation in ICU were enrolled in 4 
centres in the United Kingdom. Later, the subjects were randomized to receive 
dexmedetomidine and placebo with rescue sedation and analgesia provided by 
midazolam and morphine respectively. Compared with the control group, 
intubated patient receiving dexmedetomidine required 80o/o less midazolam 
(mean 4.9 (5.8) meg/kg/hour versus 23.7 (27.5) meg/kg/hour, p<0.0001), and 
50% less morphine (11.2 (13.4) meg/kg/hour versus 21.5 (19.4) meg/kg/hour. 
p=0.0006) (Venn, 1999). 
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From the Department of Anaestesiology, Medical College of Wisconsin and VA 
Medical Centre, 34 patients scheduled for elective inpatient surgery were 
randomized equally to receive either dexmedetomidine {initial loading dose of 
1mcg/kg over 10 min followed by 0.4mcg/kg/hour for 4 hours) or morphine sulfate 
(0.08mg/kg) 30 minutes before the end of surgery. Dexmedetomidine- treated 
patient had slower heart rate in the Post Anaesthetic Care Unit (PACU) {by an 
average of 16 bpm), whereas MAP, RR and level of sedation were similar 
between groups. Average visual analogue score tyAS) sedation scores for the 
dexmedetomidine and morphine groups were 46 ± 14 and 49 ± 20 respectively. 
During phase 1 recovery, dexmedetomidine treated patients required significantly 
less morphine to achieve equivalent analgesia {PACU dexmedetomidine group, 
4.5 ± 6.8 mg; morphine group, 9.2 ± 5.2 mg). Sixty minutes into recovery only 6 
of 17 dexmedetomidine patients required morphine in contrast to 15 of 17 in the 
morphine group (Shahbaz, 2004). 
A prospective, randomized trial in a paediatric intensive care unit in a tertiary 
center sought to compare the efficacy of midazolam versus dexmedetomidine for 
sedation during mechanical ventilation in infants and children. Continuous 
infusion of . either midazolam (starting dose of 0.1 mg/kg/hour) or 
dexmedetomidine (starting dose of either 0.25 or 0.5 meg/kg/hour) with 
intermittent morphine, as needed was given. There were 1 0 patients in each 
group. Sedation was equivalent in the 3 groups. There were 36 morphine 
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boluses administered to the midazolam group versus 29 and_ 20 morphine 
boluses administered . respectively to the 0.~5 and 0.5 meg/kg/hour 
dexmedetomidine groups (p= 0.02 for midazoiam versus 0.5 meg/kg/hour 
dexmedetomidine). Total morphine use (mg/kg/24 hour) was 0.74 ± 0.5, 0.55 ± 
0.38, and 0.28 ± 0.12 in the midazolam and the two dexmedetomidine groups 
respectively (p-value=not significant for midazolam versus 0.25 
dexmedetomidine, p-value=0.01 for midazolam versus 0.5 dexmedetomidine 
(Tobias and Berkenbosch, 2001). 
Washington Hospital Centre compared dexmedetomidine-based to propofol-
based sedation after coronary artery bypass graft (CABG) surgery in the ICU 
involved 25 centers in the United Stat~s and Canada. They found that there were 
no significant differences in mean Ramsay sedation scores between groups 
during assisted ventilation (4.5, dexmedetomidine versus 4.7, propofol; p=0.259). 
Mean times to weaning and extubation were similar. Median (25th, 75th 
percentiles) times to the start of weaning were 295 minutes (215, 410) for 
dexmedetomidine and 300 minutes {210, 482) for propofol. Median times to 
extubation were 41 0 minutes for dexmedetomidine and 462 minutes for propofol. 
Morphine use was significantly reduced in the dexmedetomidine group. Only 
28o/o of the dexmedetomidine patients required morphine for pain relief while 
ventilated versus 69% of propofol-based patient (p < 0.001). Mean blood 
pressure increased initially in both groups {between 30 minutes and 2 hours after 
sternal closure), then decreased to 3 mmHg below baseline after 30 minutes in 
8 
dexmedetomidine patients; whereas mean arterial pressure remained at 9 mmHg 
above baseline in propofol patients. Mean heart . rates were similar between 
. · .. 
groups throughout the study period (Daniel, 2003). 
2.2 Overview of Sedative Drugs 
2.2.1 Midazolam Hydrochloride CDormicuml 
Dormicum is a water-soluble imidazobenzodiazepine. It is presented as clear, 
colourless solution containing Smg/ml midazolam hydrochloride, oral tablets 
7.5mg or 15mg tablets. 
Cl 
Figure 2.2.1A Chemical structure of midazolam 
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Figure 2.2.1 B Midazolam 
i. Uses of Midazolam: 
Midazolam is used as short acting parenteral benzodiazepine, premedication, 
induction during general anaesthesia, sedation during short diagnostic and 
endoscopic procedures as well as during intensive care, hypnotic supplement to 
balanced anaesthesia for short procedures (anterograde amnesia). 
ii. Pharmacodynamic of Midazolam: 
a. Central Nervous System: 
Sedative, hypnotic, anxiolytic, muscle relaxant, anterograde amnesic and anti-
convulsant effects. Intensifies activity of GABA (gamma-aminobenzoic acid), a 
major inhibitory neurotransmitter of the brain. Dose dependant reduction in 
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cerebral oxygen consumpt~on and cerebral blood flow. Midazolam causes dose-
related changes in regi~nal cerebral blood flow in._ ~rain regions associated with 
the normal functioning of arousal, attention and memory (Veselis et al., 1997). 
b. Alimentary System 
Lower incidence of postoperative vomiting with midazolam-fentanyl induction 
sequence versus thiopentone-fentanyl. 
c. Cardiovascular System 
Clinically, midazolam has minimal cardiovascular effects but will cause variable 
respiratory depression. 
d. Respiratory System and Metabolic 
Midazolam impairs ventilatory response to hypercapnia, reduces tidal volume but 
offset by increase in respiratory rate. Apnoea especially when used as an 
induction agent. Midazolam decreases adrenergic but not cortisol or renin 
response to stress for metabolic response. 
iii. Pharmacokinetics of Midazolam 
The onset of midazolam's absorption is 1 to 5 minutes intravenously. It's 
bioavailability via oral route is 44%. Midazolam has 96% protein binding with 
volume of distribution of 0.8-1.5 litre/kg. Midazolam is completely metabolized in 
11 
the liver via conjugation. M~dazofam is excreted in the urine. The elimination half-
life of midazolam is 1.5 tC? 3.5 hours. Its clearance i~ _·5.8 to 9ml/minlkg. 
iv. Route and Dosage of Midazolam 
Sedation in ICU loading dose IV is 0.03- 0.3 mglkg then maintenance at 0.03 to 
0.2 mg/kg/hr. When combined with other CNS depressants, reduce dosage by 
about 30%. 
v. Contraindications/ Precautions of Midazolam 
Contraindicated in acute narrow angle glaucoma, acute alcohol intoxication, 
shock. Cautious use in elderly, chronic obstructive airway disease, congestive 
heart failure and chronic renal failure patients. 
vi. Adverse (side effects} 
The adverse effects of midazolam include euphoria, confusion, emergence 
delirium, muscle tremor, ataxia, dysphoria, dysphonia, slurred speech,_ 
hypotension, nodal rhythm, respiratory arrest, bronchospasm, nausea, vomiting 
(low incidence) and pain or induration at site of injection. 
Remarks: 
Short duration of action is due to its high lipid lipophilicity, high metabolic 
clearance and rapid rate of elimination. However, may not be true in prolonged 
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use example infusion in I_CU. Clinical effects can be reversed by flumazenil, 
physostigmine and glycopyrronium. 
2.2.2 Morohine Sulphate 
Morphine is a phenanthrine derivative. It is the prototype opioid agonist to which 
all other opioids are compared. Morphine is used for premedication, as an 
analgesic in the m~nagement of moderate to severe pain, for cancer pain and in 
the treatment of left ventricular failure. Morphine presents as 10/ 30/ 60/ 1 oo mg 
tablets, a syrup containing 2110/20 mg/ml, as 15/30 mg suppositories and as a 
clear, colourless solution for injection containing 1 0/ 15/ 30 mg/ml of morphine 
sulphate. 
Fig. 2.2.2A Chemical structure of morphine 
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use example infusion in I_CU. Clinical effects can be reversed by flumazenil, 
physostigmine and glycopyrronium. 
2.2.2 Morohine Sulphate 
Morphine is a phenanthrine derivative. It is the prototype opioid agonist to which 
all other opioids are compared. Morphine is used for premedication, as an 
analgesic in the m~nagement of moderate to severe pain, for cancer pain and in 
the treatment of left ventricular failure. Morphine presents as 10/ 30/ 60/ 1 00 mg 
tablets, a syrup containing 2/10/20 mg/ml, as 15/30 mg suppositories and as a 
clear, colourless solution for injection containing 1 0/ 15/ 30 mg/ml of morphine 
sulphate. 
Fig. 2.2.2A Chemical structure of morphine 
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Fig. 2.2.28 Morphine 
i. Pharmacodynamic of Morphine 
a. Central Nervous System 
A potent analgesic agent. Mu and kappa opioid receptor agonist. In humans, 
morphine produces analgesia, euphoria, sedation and a diminished ability to 
concentrate. The cause of pain persists, but even low doses of morphine 
increases the threshold to pain and modify the perception of noxious stimulation 
such that it is no longer experienced as pain. Continuous, dull pain is relieved by 
morphine more effectively than is sharp, intermittent pain. In contrast to 
monopioid analgesics, morphine is effective against pain arising from the viscera 
as well as from skeletal muscles, joints and integumental structures. Analgesia is 
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benzodiazepine, whereas these effects do not accompany the administration of 
either drug alone (Tomicheck et al., 1983). 
c. Respiratory system 
Morphine has potent anti-tussive action. It also depresses respiration, initially 
respiratory rate is affected than tidal volume, but as the dose of morphine 
increased, periodiC? breathing and apnoea occur. 
d. Genitourinary system 
Ureteric tone and contractions are increased. Vesicular sphincter tone increased. 
Morphine also has an anti-diuretic effect. 
e. Metabolic 
Diaphoresis and pruritus from histamine release. Increase anti-diuretic hormone. 
Secretion and causes transient decrease in adrenal steroid secretion. 
ii. Pharmacokinetics of Morphine 
The bioavailability of morphine via oral route is 30% due to first pass metabolism. 
The protein binding of morphine is about 35% and it's volume of distribution is 
3.2 litres/kg. The major pathway for the metabolism of morphine is conjugation 
which produces morphine 3 glucuronide and morphine 6 glucuronide. It also 
undergoes demethylation to normophine. Less than 1 0% is excreted unchanged 
in the urine. The conjugates of morphine are mainly excreted in the urine and 
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partially in the bile. The clearance of morphine is 15 ml/kg/min and its elimination 
half-life is 3 hours. Cummulation of morphine 6 glucuronide occurs in renal 
failure. The dosage of morphine for intramuscular and subcutaneous is 0.1-
0.2mg/kg and for intravenous is 0.05-0.2 mglkg 3-4 hourly. The peak analgesic 
effect of morphine is 20 min after IV. Its infusion rate is 0.5- 1 Omg/hour. Morphine 
is contraindicated for known allergy. Caution is needed for liver and renal 
impairment patients, head injury patients and hypovolaemic patients (Stoelting, 
1999). 
iii. Adverse I Side-effects of Morphine 
a. Central Nervous System 
The adverse effects of morphine include drowsiness, euphoria, miosis, seizure 
and muscular rigidity {use of high doses of morphine), dependence, pruritus, 
hypotension, bradycardia, respiratory depression, bronchoconstriction (use of 
high doses of morphine), urinary retention, nausea, vomiting, ileus, spasm of 
spincter of Oddi and constipation. 
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2.2.3 Dexmedetomidine (Dex) 
i. Classification 
Dexmedetomidine is a selective alpha 2 adrenoreceptor agonist. 
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Figure 2.2.3A Chemical structure of dexmedetomidine 
ii. Uses 
The uses of dexmedetomidine include sedation in initially intubated and 
' 
mechanically ventilated adult patients during treatment in a intensive care setting 
for up to 24 hours only, reduces postoperative concurrent analgesic and sedative 
requirements and being readily arousable and interactive when stimulated 
without respiratory depression. Most clinical experiences with dexmedetomidine 
are in postoperative patients. 
iii. Presentation 
Dexmedetomidine is supplied in the form of 2 ml clear glass ampoule/ vial, 100 
mcg/ml as the base. Dexmedetomidine must be diluted in 0.9% sodium chloride 
to achieve the required concentration prior to administration. 
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Figure 2.2.38 Dexmedetomidine 
iv. Pharmacodynamic/ Action of Dexmedetomidine 
a. Mechanism of action: 
Alpha 2 receptor are found in the peripheral and central nervous systems, 
platelets and many other organs, including the liver, pancreas, kidney and eye. 
Stimulation of the receptors in the brain and spinal cord inhibits neuronal firing 
causing hypotension, bradycardia, sedation and analgesia. The responses from 
other organs include decreased salivation, decreased secretion, decreased 
bowel motility, inhibition of renin release, increased glomerular filtration, 
increased secretion of sodium and water in the kidney, decreased intraocular 
pressure and decreased insulin release from the pancreas. The mechanism of 
action of dexmedetomidine differs from clonidine as it posses selective alpha 2-
adrenoreceptor agonism especially for the 2A subtype of this receptor, which 
causes it to be a much more effective sedative and analgesic agent than 
clonidine (Bhatia, 2002). 
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b. Central nervous system 
The majority of patients. receiving dexmedetomidin_~ were effectively sedated yet 
were easily arousable, a unique feature not observed with other sedatives (Venn 
RM et al, 1999). Additional sympatholytic properties include less anxiety. The 
sedative actions of dexmedetomidine are believed to be mediated primarily by 
post-synaptic alpha 2 adrenoreceptors, which in tum act on inhibitory pertussis-
toxin-sensitive G _protein, thereby increasing conductance through potassium 
channels. The site of the sedative effects of dexmedetomidine has been 
attributed to the locus ceruleus. The analgesic actions are believed to be 
mediated by a similar mechanism of action at the brain and spinal cord level. 
c. Cardiovascular system 
Dexmedetomidine does not appear to have any direct effects on the heart 
(Housmans PR., 1990). A biphasic cardiovascular response has been described 
after the administration of dexmedetomidine (Ralph Gertler et al., 2001; Dyck JB 
et al., 1993; Bloor BC et al., 1992; Hall JE et al., 2000). The bolus of 1 meg/ kg 
dexmedetomidine initially results in a transient increase of the blood pressure 
and a reflex fall in heart, especially in younger, healthy patients (Blow BC et al., 
1992). Stimulation of alpha 82 adrenoreceptor in vascular smooth muscle seems 
to be responsible for the initial rise in the blood pressure, which can be 
attenuated by a slow infusion. However, even at slower infusion rates, the 
increase in mean arterial pressure over the first 1 0 minutes was shown to be in 
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the range of 7%, with a de~rease in heart rate between 16% and 18% (Hall JE et 
al., 2000). The initial response lasts for 5 to 10 minutes and is followed by a slight 
. · .. 
decrease in blood pressure due to the inhibition of the central sympathetic 
outflow. 
The presynaptic alpha 2 adrenoreceptors are also stimulated decreasing the 
norepinephrine rel~ase resulting in fall blood pressure and heart rate (Aantaa R 
et al., 1990). These effects may also be observed in the postoperative period, 
and can be easily managed with atropine, ephedrine and volume infusion 
(Jalonen J et al., 1997). However, these effects may be deleterious in 
hypovolaemic patients or patients with foced stroke volume. 
d. Respiratory system 
The respiratory depression caused by dexmedetomidine has been reported to be 
much less than with other sedatives. 
v. Pharmacokinetics of Dexmedetomidine 
Dexmedetomidine exhibits linear kinetics in a dosage range of 0.2 to 0. 7 
mcg/kg/hr when administered by IV infusion for up to 24 hours. Fallowing 
infusion, dexmedetomidine exhibits a rapid distribution phase with a half-life (t '%) 
of about 6 minutes. Steady-state volume of distribution (Vss) of 
dexmedetomidine is approximately 118L. The average protein binding of 
dexmedetomidine is a 93. 7o/o. Gender and renal impairment have no effect on 
21 
protein binding, however, patients with hepatic impairment may experience 
changes in protein binding resulting in lower clearance values. There is negligible 
. -.. 
change in the plasma protein binding of dexmec:fetomidine in the presence of 
several drugs administered typically in an intensive care unit setting e.g. fentanyl, 
ketorolac, theophylline, digoxin and lidocaine. In addition, there is no significant 
plasma protein binding displacement of other drugs that can be co-administered 
with dexmedetomidine (e.g. phenytoin, ibuprofen, propranolol, theophylline and 
digoxin). 
Dexmedetomidine undergoes almost complete hydroxylation through direct 
glucuronidation and cytochrome P450 metabolism in liver. Metabolites are 
excreted in the urine (about 95%) and in the feces (4%). It is unknown whether 
they posses intrinsic activity. The elimination half-life is approximately 2 hours. It 
may be necessary to decrease the dose in patients with hepatic failure, since 
they will have lower rates of metabolism of the active drug. In cases of renal 
failure, the metabolites may accumulate, the effects of which have not been 
studied. 
vi. Dosage and clinical duration 
Dosing for ICU sedation: initial loading infusion of 1 meg/kg over 10 minutes. 
followed by a maintenance infusion of 0.2-0.7 meg/kg/hour (individualized and 
titrated to clinical effect). 
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vii. Contraindication/ Precautions 
Dexmedetomidine hydrochloride is contraindicated in patients with a known 
. . . 
hypersensitivity to dexmedetomidine. Reports of bradycardia and hypotension 
have been associated with dexmedetomidine. If medical intervention is required, 
treatment may include increasing the rate of fluid administration, elevation of 
lower extremities or use of vasopressor agents. The intravenous administration 
of anticholinergics (e.g. atropine) should be considered to modify vagal tone. 
Caution should be exercised when administering dexmedetomidine to patients 
with advanced heart block. In addition, transient hypertension has been observed 
primarily during the loading dose, associated with initial peripheral 
vasoconstrictive effects of dexmedetomidine. If intervention is necessary, 
reduction of loading infusion rate may be desirable. Dexmedetomidine should not 
be co-administered through the same intravenous catheter with blood or plasma 
because physical compatibility has not been established. Dexmedetomidine is 
primarily metabolized in the liver. Dose reduction should be considered in 
patients with hepatic impairment. 
viii. Adverse/ side-effects of Dexmedetomidine 
Bolus dosing of dexmedetomidine is to be avoided as it may be associated with 
transient hypertension, bradycardia, and sinus arrest in presence of 
hypovolaemia or high sympathetic tone. Patient may also experience nausea, 
vomiting, pain, fever and oliguria. Apart from that, patient may develop 
haematologic manisfestations such as anaemia and leukocytosis. 
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ix. Drug interactions of ~exmedetomidine 
a. General 
In vitro studies indicate that clinically relevant cytochrome P450 mediated drug 
interaction are unlikely. 
b. Anaesthetics/ ~edatives/ hypnotics/ opioids 
co .. administration of dexmedetomidine is likely to lead to an enhancement of 
effects with anaesthetics, sedative, hypnotics and opioids. Specific studies have 
confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil and 
midazolam. No pharmacokinetic interactions between dexmedetomidine and 
isotlurane, propofol, alfentanil and midazolam were demonstrated. However, due 
to pharmacodynamics effects, when co-administered with dexmedetomidine, a 
reduction in dosage with these agents may be required. 
c. Neuromuscular blockers 
No clinically meaningful increases in the magnitude of neuromuscular blockade 
and no pharmacokinetic interactions were observed with dexmedetomidine and 
rocuronium administration. 
d. Carcinogenesis, mutagenesis, impairment of fertility . 
Animal carcinogenicity studies have not been performed with dexmedetomidine. 
Dexmedetomidine was not mutagenic in vitro. Dexmedetomidine did not affect 
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